Nanosuspension coated multiparticulates for controlled delivery of albendazole

References

• Jochem A, Kansy M. High throughput solubility measurement in drug discovery and development. Adv Drug Deliv Rev. 2007;59(7):546–567.
   PubMed Web of Science ®Google Scholar
• Ashwini M, Mithun B. Sugars as solid dispersion carrier to improve solubility and dissolution of the BCS class II drug: clotrimazole. Drug Dev Ind Pharm. 2016;44:28–38.
   Google Scholar
• Gurpreet KS, Neel NS. Process, optimization, and characterization of budesonide loaded nanostructured lipid carriers for the treatment of inflammatory bowel disease. Drug Dev Ind Pharm. 2018;44:1078–1089.
   PubMed Web of Science ®Google Scholar
• Rainboe BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov. 2004;3(9):785–796.
   PubMed Web of Science ®Google Scholar
• Nagaraj K, Narendar D, Kishan V. Development of olmesartan medoxomil optimized nanosuspension using the Box–Behnken design to improve oral bioavailability. Drug Dev Ind Pharm. 2017;43(7):1186–1196.
   PubMed Web of Science ®Google Scholar
• Ying X, Xiaoyi L, Ruyue L, et al. Enhanced dissolution and oral bioavailability of aripiprazole nanosuspensions prepared by nanoprecipitation/homogenization based on acid–base neutralization. Int J Pharm. 2012;438(1):287–295.
   PubMedGoogle Scholar
• Gao L, Liu G, Kang J, et al. Paclitaxel nanosuspensions coated with P-gp inhibitory surfactants: I. Acute toxicity and pharmacokinetics studies. Colloids Surf B Biointerfaces. 2013;111:277–281.
   PubMed Web of Science ®Google Scholar
• Nakarani M, Patel P, Patel J, et al. Cyclosporine a-nanosuspension: formulation, characterization and in vivo comparison with a marketed formulation. Sci Pharm. 2010;78(2):345–361.
   PubMedGoogle Scholar
• Tingjie Y, Han C. Biological evaluation of PEG modified nanosuspension based on human serum albumin for tumor targeting delivery of paclitaxel. Eur J Pharm. 2016;83:79–87.
   Google Scholar
• Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol. 2004;56(7):827–840.
   PubMed Web of Science ®Google Scholar
• Gisela P, Agustina G. Chitosan microparticles: influence of the gelation process on the release profile and oral bioavailability of albendazole, a class II compound. Drug Dev Ind Pharm. 2014;40:1476–1482.
   PubMed Web of Science ®Google Scholar
• Cook GC. Use of benzimidazole chemotherapy in human helminthiases: indications and efficacy. Parasitol Today. 1990;6(4):133–136.
   PubMedGoogle Scholar
• [cited 2020 July 15]; 2020. Available from: http://www.drugbank.ca/drugs/DB00518html
   Google Scholar
• Van Nieuwkerk KMJ, Veenstra J, Wassenaar RP, et al. Pancreatitis causes by rupture of liver hydatid cyst. Eur J Gastroenterol Hepatol. 1993;5:563–565.
   Web of Science ®Google Scholar
• Jung H, Medina L, Garcia L, et al. Absorption studies of albendazole and some physicochemical properties of the drug and its metabolite albendazole sulphoxide. J Pharm Pharmacol. 1998;50(1):43–48.
   PubMed Web of Science ®Google Scholar
• Castillo JA, Palomo-Canales J, Garcia JJ, et al. Preparation and characterization of albendazole beta-cyclodextrin complexes. Drug Dev Ind Pharm. 1999;25(12):1241–1248.
   PubMed Web of Science ®Google Scholar
• Kohri N, Yamayoshi Y, Xin H, et al. Improving the oral bioavailability of albendazole in rabbits by the solid dispersion technique. J Pharm Pharmacol. 1999;51(2):159–164.
   PubMed Web of Science ®Google Scholar
• Pensel PE, Castro S, Allemandi D, et al. Enhanced chemoprophylactic and clinical efficacy of albendazole formulated as solid dispersions in experimental cystic echinococcosis. Vet Parasitol. 2014;203(1–2):80–86.
   PubMed Web of Science ®Google Scholar
• Rajaiya P, Mishra R. Solubility and dissolution enhancement of albendazole by spherical crystallization. Asian J Biomed Pharm Sci. 2016;6(52):9–14.
   Google Scholar
• García A, Barrera MG, Piccirilli G, et al. Novel albendazole formulations given during the intestinal phase of Trichinella spiralis infection reduce effectively parasitic muscle burden in mice. Parasitol Int. 2013;62(6):568–570.
   PubMed Web of Science ®Google Scholar
• Xiao S, You J. Augmented bioavailability and cysticidal activity of albendazole reformulated in soybean emulsion in mice infected with Echinococcus granulosus or Echinococcus multilocularis. Acta Tropica. 2002;82(1):77–84.
   PubMed Web of Science ®Google Scholar
• Wen H, New RR, Muhmut M, et al. Pharmacology and efficacy of liposome-entrapped albendazole in experimental secondary alveolar echinococcosis and effect of coadministration with cimetidine. Parasitology. 1996;113(2):111–121.
   PubMedGoogle Scholar
• María Esperanza A, Marisa P, Magali B. Synthesis and characterization of mesoporous SBA-15 and SBA-16 as carriers to improve albendazole dissolution rate. Saudi Pharm J. 2020;28(1):15–24.
   PubMed Web of Science ®Google Scholar
• Rao MR, Bajaj A. Study of effect of variables on particle size of telmisartan nanosuspensions using Box–Behnken design. Drug Res (Stuttg). 2014;64(12):663–667.
   PubMedGoogle Scholar
• Dandekar P, Jain R, Kumar C, et al. Curcumin loaded pH-sensitive nanoparticles for the treatment of colon cancer. J Biomed Nanotechnol. 2009;5(5):445–455.
   PubMed Web of Science ®Google Scholar
• Ravichandran R. Preparation and characterization of albendazole nanosuspensions for oral delivery. Int J Green Nanotechnol Biomed. 2010;2(1):B21–B24.
   Google Scholar
• Cartensen J. ICH guidelines. In: Jens T. Carstensen, C.T. Rhodes, editors. Drug stability principles and practices. Vol. 2. New York: Marcel Dekker; 1995. p. 514–546.
   Google Scholar
• Kitzman D, Cheng K-J, Fleckenstein L. HPLC assay or albendazole and metabolites in human plasma. J Pharm Biomed Anal. 2002;30(3):801–813.
   PubMed Web of Science ®Google Scholar
• Gazzaniga A, Maroni A, Sangalli ME, et al. Time-controlled oral delivery systems for colon targeting. Expert Opin Drug Deliv. 2006;3(5):583–597.
   PubMedGoogle Scholar
• Piseck R, Korselj V, Vrecer F. Comparison of direct rotor pelletization (fluid bed) and high shear pelletization method for pellet production. Pharm Biopharm. 2005;67(2):243–248.
   Google Scholar
• Akhgari A, Afrasiabi GH, Sadeghi F, et al. Statistical optimization of indomethacin pellets coated with pH-dependent methacrylic polymers for possible colonic drug delivery. Int J Pharm. 2005;305(1–2):22–30.
   PubMed Web of Science ®Google Scholar
• Indian Pharmacopoeia. Volume 1 Government of India, Ministry of Health and Family Welfare. Ghaziabad: Indian Pharmacopoeial Commission; [cited 2015 Jan 1]; 2014.
   Google Scholar
• Yumoto R, Murakami T, Nakamoto Y, et al. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. J Pharmacol Exp Ther. 1999;289(1):149–155.
   PubMed Web of Science ®Google Scholar
• Garcia JJ, Bolás-Fernández F, Torrado JJ. Quantitative determination of albendazole and its main metabolites in plasma. J Chromatogr B Biomed Sci Appl. 1999;723(1–2):265–271.
   PubMedGoogle Scholar
• Bajaj A, Rao MRP, Pardeshi A, et al. Nanocrystallization by evaporative antisolvent technique for solubility and bioavailability enhancement of telmisartan. AAPS PharmSciTech. 2012;13(4):1331–1340.
   PubMed Web of Science ®Google Scholar
• Milton JR. Chapter 2: adsorption of surface-active agents at interfaces. In: Milton J. Rosen, Joy T. Kunjappu, editors. Surfactants and interfacial phenomena. 3rd ed. New York (NY): John Wiley & Sons, Inc.; 2004. p. 38–39.
   Google Scholar
• Gupta RB. Polymer or protein stabilized nanoparticles from emulsion. In: Gupta RB, Kompella UB, editors. Nanoparticulate technology for drug delivery. New York: Taylor & Francis Group; 2006. p. 87–90.
   Google Scholar
• Terayama H, Inada K, Nakayama H, et al. Preparation of stable aqueous suspension of a hydrophobic drug with polymers. Colloids Surf B Biointerfaces. 2004;39(4):159–164.
   PubMed Web of Science ®Google Scholar
• Cabane B. Structure of some polymer-detergent aggregates in water. J Phys Chem. 1977;81(17):1639–1645.
   Web of Science ®Google Scholar
• Tadros TF. Applied surfactants. Principles and applications. Weinheim (Germany): Wiley VCH Verlag GmbH and Co.KGaA; 2005. p. 45.
   Google Scholar
• Tung H, Paul EL, Midler M, et al. Crystallization of organic compounds: an industrial perspective. New Jersey: John Wiley & Sons; 2009. p. 289.
   Google Scholar
• Nakarani M, Misra AK, Patel JK, et al. Itraconazole nanosuspension for oral delivery: formulation, characterization and in vitro comparison with marketed formulation. Daru J Pharm Sci. 2010;18(2):84–90.
   Web of Science ®Google Scholar
• [cited 10 Mar 2021]; 2021. Available from: https://en.wikipedia.org/wiki/Reynolds_number
   Google Scholar
• Koradia K, Koradia H, Sheth N, et al. The impact of critical variables on properties of nanosuspension: a review. Int J Drug Dev Res. 2015;7(1):150–161.
   Google Scholar
• Adinarayana G, Adhiyaman R, Lee M. Preparation and characterization of cefuroxime axetil solid dispersions using hydrophilic carriers. Int J Pharm Investig. 2015;5(3):171–178.
   PubMed Web of Science ®Google Scholar
• Disang F, Tingting P, Zhengwei H, et al. Polymer–surfactant system based amorphous solid dispersion: precipitation inhibition and bioavailability enhancement of itraconazole. Pharmaceutics. 2018;10(2):53.
   Web of Science ®Google Scholar
• Borchardt R, Kerns E, Lipinski C, et al. Pharmaceutical profiling in drug discovery for lead selection. Arlington (USA): American Association of Pharmaceutical Science; 2004. p. 107–108.
   Google Scholar
• Chu KA, Yalkowsky SH. Predicting aqueous solubility: the role of crystallinity. Curr Drug Metab. 2009;10(10):1184–1191.
   PubMed Web of Science ®Google Scholar
• Papadimitriou S, Bikiaris D, Avgoustakis K, et al. Chitosan nanoparticles loaded with dorzolamide and pramipexole. Carbohydr Polym. 2008;73(1):44–54.
   Web of Science ®Google Scholar
• Pranzo M, Cruickshank D, Coruzzi M, et al. Enantiotropically related albendazole polymorphs. J Pharm Sci. 2010;99(9):3731–3742.
   PubMed Web of Science ®Google Scholar
• Faheem M, Peter MM, Madeleine SAT. Preparation of albendazole-loaded liposomes by supercritical carbon dioxide processing. Artif Cells Nanomed Biotechnol. 2018;46(Suppl. 3):S1186–S1192.
   PubMedGoogle Scholar
• Ghanbarzadeh S, Khalili A, Jouyban A, et al. Dramatic improvement in dissolution rate of albendazole by a simple, one-step, industrially scalable technique. Res Pharm Sci. 2016;11(6):435–444.
   PubMed Web of Science ®Google Scholar
• Sawatdee S, Atipairin A, Attawadee S, et al. Formulation development of albendazole-loaded self-microemulsifying chewable tablets to enhance dissolution and bioavailability. Pharmaceutics. 2019;11(3):134.
   PubMed Web of Science ®Google Scholar
• Gazzaniga A, Sangalli ME, Bruni G, et al. The use of beta-cyclodextrin as a pelletization agent in the extrusion/spheronization process. Drug Dev Ind Pharm. 1998;24(9):869–873.
   PubMed Web of Science ®Google Scholar
• Bianchini R, Bruni G, Gazzaniga A, et al. Influence of extrusion spheronization processing on the physical properties of d-indobufen pellets containing pH adjusters. Drug Dev Ind Pharm. 1992;18(14):1485–1503.
   Web of Science ®Google Scholar
• Gazzaniga A, Giordano F, Sangalli ME, et al. Oral colon-specific drug delivery: design strategies. STP Pharma Prat. 1994;4:336–343.
   Web of Science ®Google Scholar
• Saurabh S, Garima M. Fluid bed technology: overview and parameters for process selection. Int J Pharm Sci Drug Res. 2010;2(4):236–246.
   Google Scholar
• Patrick JS. Martins physical pharmacy and pharmaceutical sciences. 5th ed. New York: Lippincott Williams & Williams; 2006. p. 337–340.
   Google Scholar
• Costa P, Sousa J, Lobo M. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13(2):123–133.
   PubMed Web of Science ®Google Scholar
• Larsh JE, Race GJ. Allergic inflammation as a hypothesis for the expulsion of worms from tissues: a review. Exp Parasitol. 1975;37(2):251–266.
   PubMed Web of Science ®Google Scholar
• Parsa A, Saadati R, Zahra A, et al. Enhanced permeability of etoposide across everted sacs of rat small intestine by vitamin E-TPGS. Iran J Pharm Res. 2013;12:37–46.
   PubMed Web of Science ®Google Scholar
• Bittner B, Guenzi A, Fullhardt P, et al. Improvement of the bioavailability of colchicine in rats by co-administration of d-alphatocopherol polyethylene glycol 1000 succinate and a polyethoxylated derivative of 12-hydroxy-stearic acid. Arzneimittelforschung. 2002;52(9):684–688.
   PubMed Web of Science ®Google Scholar
• Jacob S, Nair A, Shah J. Emerging role of nanosuspensions in drug delivery systems. Biomater Res. 2020;24(1):3.
   PubMedGoogle Scholar
• Wang X, Gu Y, Ren T, et al. Increased absorption of mangiferin in the gastrointestinal tract and its mechanism of action by absorption enhancers in rats. Drug Dev Ind Pharm. 2013;39(9):1408–1413.
   PubMed Web of Science ®Google Scholar
• Dominique K, Mickaël R, Cédric N. Membrane drug transport in helminths. Anti-Infect Agents Med Chem. 2010;9(3):113–129.
   Google Scholar
• He Y, Park K. Effects of the microparticle shape on cellular uptake. Mol Pharm. 2016;13(7):2164–2171.
   PubMedGoogle Scholar
• Contini C, Schneemilch M, Gaisford S, et al. Nanoparticle membrane interactions. J Exp Nanosci. 2017;13(1):1–21.
   Web of Science ®Google Scholar
• Estal JL, Alvarez AI, Villaverde C, et al. Effect of surfactants on albendazole absorption. J Pharm Biomed Anal. 1991;9(10–12):1161–1164.
   PubMed Web of Science ®Google Scholar
• Alvarez L, Lifschitz A, Entrocasso C, Manazza J, et.al. Evaluation of the interaction between ivermectin and albendazole following their combined use in lambs. J Vet Pharmacol Therap. 2008;31:230–239.
   Google Scholar
• Lange H, Eggers R, Bircher J. Increased systemic availability of albendazole when taken with a fatty meal. Eur J Clin Pharmacol. 1988;34(3):315–317.
   PubMed Web of Science ®Google Scholar
• Dayan AD. Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics. Acta Trop. 2003;86(2–3):141–159.
   PubMed Web of Science ®Google Scholar
• Dey NS, Majumdar S, Rao MEB. Multiparticulate drug delivery systems for controlled release. Trop J Pharm Res. 2008;7(3):1067–1075.
   Web of Science ®Google Scholar